Answer
Its licensed uses are limited to cancers with particular activating EGFR mutations. A validated tumour-tissue or plasma test confirms whether the cancer matches an approved use.
Sources for this answer
- Rybrevant (amivantamab) 1600mg solution for injection — Current selected SmPCemc · Summary of Product Characteristics
- Rybrevant (amivantamab) 350mg concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.